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Summary Primary tumours of the central nervous system (CNS) are an important cause of cancer-related
deaths in adults and children. CNS tumours are mostly glial cell in origin and are predominantly astrocytomas.
Conventional therapy of high-grade gliomas includes maximal resection followed by radiation treatment. The
addition of adjuvant chemotherapy provides little improvement in survival time and hence assessment of novel
therapies is imperative. We have evaluated the potential therapeutic use of the herpes simplex virus (HSV)
mutant 1716 in the treatment of primary brain tumours. The mutant is deleted in the RLI gene and fails to
produce the virulence factor ICP34.5. 1716 replication was analysed in both established human glioma cell lines
and in primary cell cultures derived from human tumour biopsy material. In the majority of cultures, virus
replication occurred and consequential cell death resulted. In the minority of tumour cell lines which are non-
permissive for mutant replication, premature shut-off of host cell protein synthesis was induced in response to
lack of expression of ICP34.5. Hence RLI-negative mutants have the distinct advantage ofproviding a double
hit phenomenon whereby cell death could occur by either pathway. Moreover, 1716, by virtue of its ability to
replicate selectively within a tumour cell, has the potential to deliver a 'suicide' gene product to the required
site immediately. It is our opinion that HSV which fails to express ICP34.5 could provide an effective tumour
therapy.
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The poor prognosis following surgery and radiation
treatment of patients with glioblastoma multiforme and
other malignant gliomas has led to intensive efforts in the
search for alternative therapies (Chang et al., 1983). More
aggressive surgery (Albert et al., 1994) and focused radio-
therapy (Mehta et al., 1994) are possibly associated with
improved survival but cure is likely to remain elusive with
these techniques alone because of the adverse growth
characteristics of gliomas (Kelly et al., 1987). Chemotherapy
offers the possibility of entire regional treatment but its
impact on glioma therapy has been modest (Fine et al., 1993).
This is due to a number of factors including penetration
problems, the intrinsic lack of efficacy of the available agents
(Kornblith and Walker, 1988), the heterogeneity of tumours
(Allalunis et al., 1992) and adverse conditions in the
associated microenvironment (Rampling et al., 1994). There
is a clear need for alternative therapies.
One approach has been to use viruses, either to deliver a
therapeutic gene (Oldfield et al., 1993) or as killing agents in
their own right (Martuza et al., 1991). This latter approach
has particular appeal in the central nervous system (CNS)
where the proliferative activity of the tumour distinguishes it
from the surrounding normal brain which is essentially non-
proliferative. Effective viral therapy in rodents based on
replication-deficient mutants of herpes simplex virus type 1
(HSV-1) have been described (Mineta et al., 1995).
Herpes simplex virus is a large double-stranded DNA
virus whose genome consists of two unique segments, long
and short, each bounded by a set of inverted repeats. The
long repeat region of the genome contains a diploid gene,
RLI (Chou and Roizman, 1986; Dolan et al., 1992) whose
protein product ICP34.5 is a major determinant of
pathogenicity (Chou et al., 1990; MacLean et al., 1991;
McKie et al., 1994). We have previously isolated an HSV-1
mutant 1716 which has a 759 bp depletion in both copies of
RL1 (MacLean et al., 1991). This mutant has a markedly
attenuated ability to replicate in the CNS following both
corneal and footpad inoculation of mice, and has an LD50
106-fold higher than its parental strain 17+ following
intracerebral inoculation. In vitro 1716 and other RLI null
mutants replicate as efficiently as their parental virus in
established dividing cell lines from different species but
replicate poorly in non-dividing cells (MacLean et al., 1991;
Brown et al., 1994a).
It has previously been shown in one human neuroblastoma
cell line SK-N-SH that mutants which fail to express ICP34.5
grow poorly and are specifically unable to prevent shut-off of
cellular protein synthesis (Chou and Roizman, 1992), whereas
infection of Vero cells which are non-neuronal in origin
results in sustained protein synthesis and production of
infectious progeny. Therefore in cells of neuronal origin
ICP34.5 provides a survival mechanism which enables the
virus to sustain its replication cycle and produce infectious
virus. In the context of brain tumour therapy, RLI deletion
mutants have been identified as being of potential use since
they should replicate preferentially in tumour cells, which
constitute a mass of dividing cells within an otherwise
quiescent population, non-permissive for viral replication.
RL1 null mutants have the additional advantage in some cell
lines that they provide a double hit phenomenon whereby cell
killing should occur not only through lysis owing to growth
and release of replicating virus, but also by premature shut-
off of host cell protein synthesis. However, since the
requirement of HSV-1 for ICP34.5 is both cell type- and
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cell state-specific (Brown et al., 1994a), it cannot be assumed
at this stage that RL1 mutants will provide effective killing of
all tumour cell types.
The therapeutic potential of RL1 mutants has so far been
assessed in xenograph tumour models in animals (Markert et
al., 1993; Chambers et al., 1995; Randazzo et al., 1995). Of
necessity these model systems, although providing important
information, cannot mimic the human situation where human
heterogeneity and host environment can influence tumour
and treatment behaviour. We therefore considered it
important to determine whether RL1-negative HSV could
kill naturally occurring human CNS tumours. To evaluate
the potential efficacy of RL1 deletion mutants in the
treatment of malignant glioma we have analysed viral
replication in vitro in biopsy material obtained from patients
with anaplastic astrocytoma or glioblastoma multiforme. In
addition, we have assessed quantitatively the ability of the
virus to grow in established human glioma cell lines in vitro.
Owing to the inability to establish and grow sufficient
numbers of cells, we were unable to obtain cultures of
normal human brain tissue in sufficient quantities for
comparative growth analysis.
Materials and methods
Cells
Baby hamster kidney clone 13 cells [BHK-21(C13); Mac-
Pherson and Stoker, 1962] were propagated in Eagle medium
containing twice the normal concentration of vitamins and
amino acids, 5% tryptose phosphate broth and 10% (v/v)
fetal calf serum (FCS). The established human glioma cell
lines used in this study are outlined in Table I. T98G, SB18,
U-373MG, U-87MG, U251 were obtained from the
European Tissue Culture Collection; MCN(X) was derived
in the Medical Oncology Department and was obtained from
Dr Pilkington, London. All established cell lines were
propagated in a 50:50 mixture of Ham's F-10 medium and
Dulbecco's modified Eagle medium (DMEM) containing
10% FCS, 5% L-glutamine and 50 jug ml-' gentamicin. To
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establish primary glioma cultures in vitro, glioma tissue was
excised from patients undergoing cranial surgery in
accordance with ethical procedures and a portion was
placed immediately into ice-cold modified DMEM lacking
serum; DMEM-BS (Bottenstein and Sato, 1979) containing
25 Mg ml-1 gentamicin. Tissue was not screened for presence
of virus. The tumour tissue was finely chopped and
collagenase (13.3 mg ml-'; ICN Biochemicals, USA) mixed
1:1 (v:v) with L15 medium (Gibco) was added. The
collagenase/tumour mixture was incubated for 30 min at
room temperature and pipetted up and down with a 19-gauge
needle to dissociate the tissue into single cells. The resulting
cell suspension was washed in L15 medium and spun down at
2000 r.p.m. for 5 min. The cell pellet was split and
resuspended in either 4 ml of DMEM-BS medium contain-
ing 1:1 (v:v) medium conditioned for type 1 astrocytes (Noble
and Murray, 1984) or DMEM-BS containing 20% FCS; both
cultures containing 25 jg ml-1 gentamicin. Cells in the
appropriate media were incubated on 25 cm3 tissue culture
flasks coated with 13 Mg ml-' poly-L-lysine (Sigma) and
incubated in 7% carbon dioxide at 37°C. For subsequent
analysis of viral growth characteristics, cultures were
expanded in a 50:50 mixture of DMEM and Ham's F-10
Table I Origin of cell lines tested for HSVI wild-type and RLl
mutant 1716 replication
Cell line Origin
Established cell lines
MCN(X) Human adult glioma passaged in vivo in
mice; cell line established in vitro
T98G, SB18 U251 Human glioblastoma multiforme
U-87MG, U-373MG Human glioblastoma astrocytoma
Cell lines derived from human tumour biopsy material
BG557, BG398, BG448 Anaplastic astrocytoma
G-AST
BG535, BG560, BG500 Glioblastoma multiforme
BG550, BG555
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Figure 1 Growth kinetics of HSV-1 strain 17+ (-U-) and the RLl-negative mutant 1716 (....A....) SB18, T98G and U251 cells
were infected at a multiplicity of infection (m.o.i.) of 10 p.f.u. per cell (upper graph) or 0.001 p.f.u. per cell (lower graph), and at
various times after infection the infected cells were harvested. The virus was released by sonication and titrated on BHK-21 (C13)
cells at 37°C: (a) SB18 cells; (b) T98G cells and (c) U251 cells. Graphs shown are accurate representations of results obtained from
more than one assay.CNS tumour therapy using HSV-1
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medium with antibiotics as above. Table I gives a summary
of the origins of the cell lines established.
Viruses
Virus stocks were grown and titrated on BHK21/C13 cells as
previously described (Brown et al., 1973). The parental HSV-
1 strain used in this study was Glasgow strain 17+ (Brown et
al., 1973) and the RL1 mutant was 1716 (MacLean et al.,
1991)
Virus growth properties in vitro
Approximately 2 x 106 cells were infected either at a
multiplicity of 10 plaque-forming units (p.f.u.) per cell
(single cycle) or 0.001 p.f.u. per cell (multiple cycles) with
parental strain 17+ or RLl mutant 1716. After absorption
for 45 min at 37°C, the monolayers were washed, overlaid
with the appropriate medium and incubated at 37°C. At
intervals up to 24 h (single cycle) or 72 h (multiple cycles)
after infection, samples were harvested and virus released by
sonication was titrated on BHK21/Cl3 cells. Growth
experiments were carried out in all the cell lines listed above.
Immunofluorescence
Linbro wells containing coverslips were seeded with
approximately 5 x 104 cells and incubated at 37°C over-
night. Cells on coverslips were mock infected or infected at a
multiplicity of infection (m.o.i.) of 10 p.f.u. per cell with
parental or mutant viruses. Following incubation at 37°C for
10 h, cells were fixed with 4% paraformaldehyde for 15 min
at room temperature, washed twice with phosphate-buffered
saline (PBS) and stored in 70% ethanol at -20°C until use.
Coverslips were incubated initially with the monoclonal
antibody ZIFI1, which recognises the HSV-1 65K DNA-
binding protein (kindly provided by Dr H Marsden);
fluorosciene isothiocyanate conjugated goat anti-mouse IgG
(Southern Biotechnique, Europath) was used as a second
antibody. In some experiments cells were also stained with a
rabbit polyclonal antiserum (Southern Biotechnique, Euro-
path) against the glial fibrillary acidic protein (GFAP)
(Southern Biotechnique, Europath) an astrocytic specific
marker. In this case, rhodamine-conjugated goat anti-rabbit
IgG (Europath) was used as a second antibody. Cells were
viewed using a Nikon Microphot SA microscope.
Labelling of infected cells with [35S]methionine
Linbro wells containing either BG398, BG500 or BG560 cells
were separately infected at a m.o.i. of 10 p.f.u. per cell with
HSV-1 strain 17+ and 1716. At various times after infection,
the cells were washed twice with PBS and the media replaced
with PBS containing 50 ,uCi ml-' [35S]methionine. Labelling
was continued for 1 h after which time the cells were
harvested and protein extract from 2 x 105 cells separated
using 7.5% SDS-PAGE as previously described (Marsden et
al., 1978).
Results
Growth characteristics of HSV-1 strain 17 and the mutant
1716 in established human glioma cell lines
In BHK21/C13 cells, which are routinely used for propaga-
tion and titration of HVS-1, wild-type virus and RL1 deletion
mutants grow with indistinguishable kinetics at both high and
low multiplicities of infection (MacLean et al., 1991; McKie
et al., 1994). However, this phenotype is not reflected in all
cell lines; in 3T6 mouse embryo fibroblasts, where wild-type
HSV-1 replicates normally, RL1 mutant viruses are replica-
tion deficient (Brown et al., 1994a, b); in F9 mouse
teratocarcinoma stem cells, the phenotype is reversed and
RLI mutant virus replicates more efficiently than the wild-
type virus (Brown et al., 1994a). When F9 cells are induced
to differentiate into parietal ectoderm by the addition of
retinoic acid and dibutyryl cAMP, their permissivity for RL1
mutant virus increases while also becoming permissive for
wild-type viral replication. It is evident therefore that both
cell type and cell state determine the phenotype of HSV-1
variants which fail to synthesise ICP34.5. In order to evaluate
efficiently the potential therapeutic value of RL1 mutant virus
for the treatment of naturally occurring human brain
tumours it became important to determine whether viral
replication and cell killing was a predominant response in a
wide range of tumour and established glioma cell lines in
vitro.
Preliminary experiments were carried out at both high and
low multiplicities of infection. Figure 1 shows the results of
single and multi-cycle growth experiments with an initial
infectingmultiplicityofeither 10 or0.001 p.f.u. percell. Thecell
lines used were the established human glioma cell lines T98G,
SB18 and U251. In all three cases the growth patterns ofwild-
type and mutant virus were similar with a 102_ to 103-fold
increase in titre during the exponential phase ofgrowth at high
multiplicities ofinfection. However, in all cases growth of 1716
lagged slightly behind that of wild-type, subsequently leading
to a lower final yield of virus. At lower multiplicities of
infection, which determine the ability ofthe virus to be released
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Figure 2 Growth kinetics of HSV-1 strain 17+ (-U-) and the
RLI-negative mutant 1716 (-A-). (a) U-373MG and (b) U-87MG
cells were infected at an m.o.i. of 10 p.f.u. per cell and at various
times after infection the infected cells were harvested. The virus
was released by sonication and titrated on BHK-21 (C13) cells at
37°C. Subsequent experiments demonstrated almost identical
results.
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from infected cells and undergo further rounds ofreplication,
both mutant and wild-type viruses showed similar growth
kinetics in allcelllinestested although thefinal titre of1716 was
reduced compared with the wild-type infection.
Several other established human glioma cell lines were
tested for their ability to sustain viral replication at high
multiplicities ofinfection (Figure 2). These included MCN(X),
U-87MG and U-373MG. In both MCN(X) and U-373MG
1716 and 17+ grew efficiently, showing 102_ to 103-fold
increases in titre during the exponential phase of growth. In
U-87MG cells, 17+ also showed a 102_ to 103-fold increase in
titre during the exponential phase of growth, whereas 1716
showed limited replication in this cell line. Interestingly, both
viruses failed to replicate in MCX(X) cells (data not shown)
andunlike primary tumourcellswhichwerenon-permissive for
HSV (e.g. BG500) this cell line showed no signs ofviral c.p.e.
Growth of wild-type and RLI mutant virus in tumour biopsy
material
Having established that the RLI-negative mutant virus 1716
can replicate efficiently and destroy established human glioma
cell lines in vitro, we wished to determine whether it was also
effective in killing tumour cells obtained from patients
undergoing cranial surgery. In all cases, cells were passaged
as few times as possible to maintain their phenotype and limit
selection for a subpopulation of rapidly growing cells. All
cells were used at pass numbers between 2 and 4.
A total of nine tumour-derived cell lines from patients
diagnosed as having either anaplastic astrocytoma or
glioblastoma multiforme were tested for their ability to
sustain viral replication. Owing to the limited numbers of
cells available, virus growth experiments were only carried
out at high multiplicities of infection (Figure 3). Several 24 h
yield experiments were carried out for each cell line, where
only the titre of input virus and yield at 24 h after infection
were calculated; these demonstrated identical fold increases in
titre to those presented in the graphs. In general, both wild-
type and mutant virus replication was observed, with
increases in titres ranging from 10-fold to 3000-fold during
the exponential phase of growth. In one cell line, BG500,
1716 failed to replicate, whereas the titre of 17+ increased
-20-fold during the exponential phase of growth.
Viral antigen expression in permissive and non-permissive
cultures
To establish whether lack of 1716 replication in certain cell
lines was blocked at a stage before or after viral entry, viral
antigen expression was detected by immunofluorescence. We
studied BG500 cells, as a representative tumour-derived cell
line that was non-permissive for 1716, and MCN(X) the only
established glioma cell line tested that was totally non-
permissive for HSV-1. Cell lines that were either fully-
permissive (BG398) or semipermissive (BG560) for 1716
replication were used as controls.
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Figure 3 Growth kinetics of HSV-1 strain 17+ (---) and the RLl-negative mutant 1716 (-A-). BG500 (a), G-AST (b), BG398 (c),
BG448 (d), BG550 (e), BG560 (f), BG535 (g), BG557 (h) and BG555 (i) cells were infected at an m.o.i. of 10 p.f.u. per cell and at
various times after infection the infected cells were harvested. The virus was released by sonication and titrated on BHK-21(Cl3)
cells at 37°C. In cases where sufficient cells could be obtained to examine viral growth kinetics more than once final viral titres could
be accurately reproduced.
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1-Cells were infected as described in Materials and methods,
fixed 10 h after infection and stained with ZIFi 1, a
monoclonal antibody directed against the HSV-1 early
protein 65K (Figure 4b and 4d). The percentage of cells
expressing 65K was determined for each cell line. As
predicted from the growth experiments, 1716-infected
BG398 cultures displayed a higher proportion of antigen-
positive cells (79%) than mutant-infected BG560 (48%) or
BG500 (34%). In all cultures infected with wild-type virus,
85-95% of cells were infected at this time point and viral
yield appeared to be directly related to infectivity. There were
no antigen-positive MCN(X) cells in cultures infected with
either wild-type virus or 1716, demonstrating that HSV is
unable to initiate replication in these cells. Interestingly,
MCN(X) cells were also negative for GFAP by immuno-
fluorescence staining.
To determine whether there was a correlation between
expression of GFAP and permissivity for HSV-1, the
immunofluoresence experiments were repeated and cells were
labelled for expression of both GFAP (Figure 4a and c) and
65K. We were unable to demonstrate a correlation between
GFAP expression and HSV permissivity, as BG398 cells,
which were highly permissive for both wild-type and 1716
replication had a low percentage of GFAP positive cells
(14%) whereas BG500 which were non-permissive for 1716,
but permissive for 17+ had a high percentage of GFAP-
expressing cells (75%). There was no correlation between
expression of GFAP in any individual cell and permissivity
for HSV, as all cultures contained 65K-positive cells which
were either GFAP-positive or GFAP-negative.
Failure ofRLI mutants to replicate in some cell lines is caused
by premature shut-off ofhost cell protein synthesis
Having established in BG500 cells that the block in the viral
replication cycle is not caused by an inability of the virus to
enter the cell, we wished to determine whether the failure to
support replication of RL1 mutant virus was due to shut-off
of cellular protein synthesis. Three cell lines were selected
which varied in their permissivity for 1716: BG398, which
was fully permissive; BG560, which was semipermissive; and
BG500, which was non-permissive. Figure 5 shows the levels
of [35S]methionine incorporated into cells infected with either
wild-type or 1716 or uninfected controls.
In fully permissive BG398 cells the levels of cellular
protein synthesis are very similar following infection with
either wild-type or 1716 at all time points examined although
there appears to be a slight decrease in protein synthesis by
8-9 h after infection in cells infected with 1716. In cell lines
which are less permissive for 1716 compared with 17+ there
are reduced levels of protein synthesis in 1716-infected cells
harvested as early as 5-7 h after infection; 9 h after
infection, incorporation of [35S]methionine is markedly
reduced in BG500 and BG560 cells.
Discussion
Several studies in mice have demonstrated regression of
experimentally implanted tumours by replication-compro-
mised variants of herpes simplex virus that replicate
normally in dividing cells but fail to replicate in non-
dividing cells of the nervous system. One of the earliest
studies using a thymidine kinase (TK)-negative HSV mutant
dlsptk (Coen et al., 1989) demonstrated a dose-dependent
improvement in survival of nude mice bearing intracranial
tumours following intratumoral therapy (Martuza et al.,
1991). However, subsequent studies demonstrated that this
mutant is unsuitable for therapeutic use in humans as it can
cause encephalitis.
RL1 variants have been shown to improve the survival of
nude mice bearing intracranial human gliomas (Markert et
al., 1993; Chambers et al., 1995; Kesari et al., 1995) and have
the added advantage that they are totally non-neurovirulent
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(Chou and Roizman, 1990; MacLean et al., 1991; McKie et
al., 1994). A recent study using the Harding-Passey
melanoma cell line to establish CNS tumours in C57BI/6
mice demonstrated that stereotactic injection of the avirulent
HSV variant 1716 into the tumour 5-10 days after CNS
Figure 4 Localisation of the HSV-1 65kDa DNA-binding
protein and GFAP in infected cells. These photographs are
representative examples of (a) 17+-infected BG398 cells incubated
with anti-GFAP; (b) 1716-infected BG398 cells incubated with
ZIFI 1; and 1716-infected BG500 cells incubated with either (c)
anti-GFAP or (d) ZlFll.CNS tumour therapy using HSV-1
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Figure 5 Autoradiographs of electrophorectically separated
lysates of infected cells labelled for 60min with [35S]methionine.
(a) BG398, (b) BG560 and (c) BG500 cells in linbro wells were
either mock-infected or infected at an m.o.i. of 10 p.f.u. per cell
with 17+ or the RLl-negative mutant 1716. At various times after
infection (p.i.) the cells were harvested, lysed and extracts
separated by 7.5% SDS-PAGE. Extracts from 2 x 105 cells are
loaded in each lane. For each cell line; 1, mock, 1 h p.i.; 2, 17+,
3h p.i.; 3, 1716, 3h p.i.; 41, mc,9h p.i.; 5, 1716, Sh p.i., 6, 17+,
7h p.i.; 7, 1716, 7h p.i.; 8, 17+, 8h p.i.; 9, 1716, 8h p.i.; 10, 17+,
9h p.i.; II, 1716, 9h p.i.; 12, mock, 9h p.i.
seeding of the melanoma cells results in a significant increase
in the time to development of neurological symptoms,
complete tumour regression and long-term survival of
animals (Randazzo et al., 1995). One of the most relevant
findings from this study in terms of safety of RLI mutants
was the demonstration that in mice treated with 1716, HSV
antigen staining was contained in the tumour mass with no
spread to adjacent tissue or distant regions of the brain.
These results substantiated previous studies which showed
that following intracerebral inoculation 1716 fails to replicate
and hence fails to kill either BALB/c (MacLean et al., 1991)
or immunocompromised SCID mice (Valyi-Nagy et al.,
1994); a recent study has also demonstrated that an HSV-1
variant containing a mutation in RLI is similarly non-
neurovirulent following intracranial inoculation of owl
monkeys (Mineta et al., 1995) and we would also predict
that RL1 mutants will fail to replicate in the human CNS.
Previous studies which have used herpes simplex virus
vectors for the treatment of experimentally induced brain
tumours have been directed towards the development of
relevant in vivo models to study tumour regression and long-
term survival. Consequently, these studies have concentrated
on cell lines which are known to grow as xenographs in mice
(Markert et al., 1993; Chambers et al., 1995) with very little
quantitative analysis of viral replication in established CNS
tumour cell lines or primary tumour tissue obtained from
surgical specimens. If RL1-negative HSV is to be seriously
considered as a realistic tumour therapy, it is crucial to
ensure that the virus is capable of replicating and killing
naturally occurring tumours. Therefore, as a preliminary
prerequisite to human therapy, we have evaluated the CNS
tumour killing potential of RLI-negative HSV.
With the exception of one cell line, MCN(X), we found
that wild-type HSV-1 replicated in all cell lines tested. In
general wild-type and mutant virus showed similar replication
kinetics in cell lines derived from anaplastic astrocytoma (e.g.
G-AST and BG398), but were more variable in cells derived
from glioblastoma multiforme (e.g. BG500 and BG560). This
could be explained by the heterogeneous pathology of
glioblastoma multiforme, which could include populations
of refractile cells non-permissive for HSV. Immunofluores-
cence staining of MCN(X) demonstrated that viral gene
expression was not initiated by either wild-type virus or 1716
in these cells and unlike BG500 cells, which were also non-
permissive for 1716, these cells failed to round up and die.
The survival of MCN(X) cells following infection supports
the double-hit response hypothesis as these cells do not suffer
an infection-induced death. The failure of HSV to replicate in
this cell line could be owing to the lack of suitable cellular
receptors for adsorption and/or penetration or it could be at
a stage subsequent to virus entry.
1716 also failed to replicate in one cell line derived from
tumour biopsy material. In this case the mutant entered the
cell as indicated by expression of the 65K DNA-binding
protein yet no infectious virus was produced possibly as a
consequence of the shut-off of cellular protein synthesis
demonstrated early in infection. However, a limited number
of cells did support 1716 replication, a situation similar to
that recently demonstrated in 3T6 cells (Brown et al., 1994a).
One possible explanation for this finding is that a proportion
of the cells produce a protein which can compensate for the
loss of ICP34.5, preventing shut-off of cellular protein
synthesis thus allowing viral replication. However the decline
in protein synthesis observed in both BG500 and BG560 cells
infected with 1716 appeared similar, yet BG500 cells were
totally non-permissive for 1716 and a direct correlation
cannot be made between viral titre and degree of host cell
protein synthesis shut-off-other factors are certainly
involved. Variations in expression of proteins which are
functionally homologous to ICP34.5 could account for the
differences observed in 1716 growth or alternatively the
cellular proteins could be totally unrelated. As the cells were
infected at high multiplicities of infection, where all cells in
the culture would be expected to be infected, a difference in
a
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individual cellular metabolism or protein expression would
seem a more likely explanation than a defect in maturation
and virus egress preventing further rounds of replication as
previously shown in 3T6 (Brown 1994b).
The finding that not all tumour cells are permissive for
1716 replication is important not only in terms ofthe biology
of HSV but also in its implications for the treatment of
human gliomas. At face value it indicates that not all human
gliomas could be successfully treated using HSV RLI null
mutant therapy. The BG500 cell line was derived from a
patient with glioblastoma multiforme, the most commonly
found primary tumour of the nervous system. As indicated
by the term 'multiforme', the tumour is characterised by a
pleomorphic cellular population. Chromosome banding
techniques (Bigner et al., 1984, 1986) have indicated that
the tumour may evolve from a single malignant progenitor
cell and that the phenotypic and genotypic heterogeneity
observed is a result of secondary changes. Therefore, in
reality, every patient who presents with this form of glioma
may have a completely different tumour cell composition
which consequently may vary greatly in permissivity for RLI
null mutant replication.
We have shown that 1716 replicates - 100-fold less
efficiently than wild-type virus in U87-MG cells in vitro. In
a recent study Mineta et al. (1995) used the U-87MG cell line
to implant tumours intracerebrally into mice and demon-
strated complete tumour regression in this model when
animals were injected with 107 p.f.u. of G207, a multi-
mutated variant of HSV-1 strain F which fails to synthesise
both ICP34.5 and ribonucleotide reductase. These comple-
mentary in vivo and in vitro findings suggest that even limited
viral replication could be sufficient to enable complete
tumour regression in humans.
As demonstrated, infection with RLl-negative virus which
does not result in lytic replication in specific cell types can
trigger the host cell into premature protein synthesis shut-off.
Hence, although the tumour cells are not killed by virus
replication, the cells could die owing to cessation of protein
synthesis. HSV, RLI mutant therapy has therefore the
distinct advantage of a double-hit response. The added
potential of introducing a transgene capable of expressing a
tumour-killing agent into RLl-negative HSV is obvious. As
the mode of infection in tumour cells is lytic as opposed to
latent, long-term expression from a therapeutic gene would
not be required.
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